Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy
J. Zak, I. Pratumchai, B. S. Marro, K. L. Marquardt, R. Beheshti Zavareh, L. L. Lairson, M. B. A. Oldstone, J. A. Varner, V. Bachanova, J. Teijaro
Ruxolitinib reshapes myeloid immunity to synergize with checkpoint inhibitors, enhancing anti-tumor T cell activity and improving immunotherapy outcomes.
bioRxiv · Jun 24, 2022Immunology